The importance of the presence of Creatv MicroTech in the CC relates to their ability to measure and interpret levels of both, CTCs and macrophage-like cells (CAMLs).
Why?? Below some copy-and-paste from papers on the subject:
More importantly, there is relationship between CTCs level versus survival and prognosis of patients:
This is true for breast and other cancers. We have reported reduction ( actually, reduction to ZERO, yes 0 ) of CTCs after administration of Leronlimab. This is HUGE (forgotten now due to COVID current emphasis). However, measuring CTCs is not easy, by the contrary, is very difficult and the significant levels are (5 cells) have been found to be meaningful in some trials:
https://www.nejm.org/doi/full/10.1056/nejmoa040766
So. What is the point ??
Recent research has shown that a complementary measurement to CTCs is macrophage like cells (CAMLs) and this measurement provides an independent prognostic indicators of survival. Dr. Patterson referred to this in some of his interviews few months ago:
Creatv MicroTech is a leader of measurement of both CTCs and CAMLs and is the third point on the agenda:
This is the BIG thing. This is THE ball we should keep out eyes on. This is what will bring the price to triple digits (you can argue if high triple digits or low triple digits). So, I am really looking forward to the progress of our Oncology trial patients and, more importantly, to hear some numbers & interpretation in CTCs and CAMs.
For some idea of the potential oncology market: https://investorshangout.com/post/view?id=5876860
You all have a great weekend.
Why?? Below some copy-and-paste from papers on the subject:
Quote:Tumor cells divide from tumor tissue and enter the blood circulation, and then form tumor embolisms through migration, adhesion, and aggregation in the blood circulation. The above process is the main type of distant metastasis of breast cancer, and is also an important factor that affects the survival and prognosis of patients. Therefore, the detection of circulating tumor cells in peripheral blood of breast cancer patients plays an important role in breast cancer diagnosis, prognosis assessment, selection of treatment regimen, and prediction of metastasis and recurrence.
More importantly, there is relationship between CTCs level versus survival and prognosis of patients:
Quote:For most tumors, once distant metastasis occurs, the difficulty of treatment greatly increases and the efficacy and prognosis are worse. More than 90% of deaths in patients with malignant tumors are caused by distant metastasis and recurrence of tumor cells. Hematogenous dissemination is an important mode of distant metastasis of breast cancer. The distant metastasis of tumor cells can occur even in the early stage of breast cancer. The spreading of breast cancer cells from the primary focus and then entering the blood circulation to form CTC are the first links in distant metastasis. Detection of changes in CTC number and dynamic states can reflect tumor loading, provide early prediction of the recurrence and metastasis of non-metastatic breast cancer, monitor the development of the disease, and help clinicians to choose treatment options and take effective intervention measures to block the metastatic focus formation, and thus is important in controlling the disease, reducing recurrence, providing high curative effect, and improving prognosis. Therefore, the diagnostic and predictive value of CTC and its role in the transformation of medical research have attracted more and more attention from medical science researchers, and are now popular topics in the field of cancer research.
This is true for breast and other cancers. We have reported reduction ( actually, reduction to ZERO, yes 0 ) of CTCs after administration of Leronlimab. This is HUGE (forgotten now due to COVID current emphasis). However, measuring CTCs is not easy, by the contrary, is very difficult and the significant levels are (5 cells) have been found to be meaningful in some trials:
https://www.nejm.org/doi/full/10.1056/nejmoa040766
Quote:The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
The results of this trial indicate that in metastatic breast cancer the level of circulating tumor cells before a new therapy is initiated and, even more important, the level measured at the first follow-up visit are useful predictors of progression-free survival and overall survival. Circulating tumor-cell levels of ≥5 cells per 7.5 ml of blood
In a multivariate analysis, the predictive value of the level of circulating tumor cells, either at baseline or at the first follow-up visit, was independent of the time to metastasis, the site of metastasis (visceral as compared with nonvisceral), and hormone-receptor status.
So. What is the point ??
Recent research has shown that a complementary measurement to CTCs is macrophage like cells (CAMLs) and this measurement provides an independent prognostic indicators of survival. Dr. Patterson referred to this in some of his interviews few months ago:
Quote:In the first patient, we’re encouraged to see that after 11 weeks these additional data provide further preliminary evidence of efficacy, as demonstrated by sustained undetectable levels of CTCs and a reduction of cancer-associated macrophage like cells (CAMLs),” said Bruce Patterson, M.D., Chief Executive Officer of IncellDx. “Thus far, the data have been consistent with previous studies evaluating leronlimab as a long-term therapy for HIV+ patients, with no serious adverse effects reported in the mTNBC trial.
Creatv MicroTech is a leader of measurement of both CTCs and CAMLs and is the third point on the agenda:
Quote:Detail discussions of the cancer results and discussions from invited guest (from Creatve MicroTech) on the Leronlimab potential in all cancers based on current results in the last 1 year.
This is the BIG thing. This is THE ball we should keep out eyes on. This is what will bring the price to triple digits (you can argue if high triple digits or low triple digits). So, I am really looking forward to the progress of our Oncology trial patients and, more importantly, to hear some numbers & interpretation in CTCs and CAMs.
For some idea of the potential oncology market: https://investorshangout.com/post/view?id=5876860
You all have a great weekend.
24
